ASH 2015: Latest in CLL

Long-term outcomes after blinatumomab treatment for ALL

ASH 2015: Highlights

How is cancer-related venous thromboembolism treated in real world practice?

Dalteparin thromboprophylaxis for cancer patients at high risk of venous thromboembolism

Response to rituximab induction is a predictive biomarker in post-transplant lymphoproliferative disorder

“Low but real” risk of myelodysplastic syndromes caused by thyroid cancer treatment

High dose chemotherapy plus transplant remains standard care for young newly diagnosed multiple myeloma patients

ENDEAVOR: carfilzomib new standard in multiple myeloma?

How can functional drug screening guide personalised cancer therapy?

How do genes influence the development of chronic idiopathic thrombocytopenic purpura?

Combining treatment options for higher risk myelodysplastic syndromes and chronic myelomonocytic leukaemia

ASH 2015: Highlights in mantle cell lymphoma

Incidence of and predictors for early death in paediatric patients with acute promyelocytic leukaemia

Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype

Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia

First all-oral treatment for relapsed and treatment-resistant multiple myeloma

Experimental oral therapy for high-risk CLL shows promise

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen

ASH 2015: Novel combination approaches for multiple myeloma

ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia

ASH 2015: New targeted therapies for haematological malignancies

Using epigenetics to manipulate cancer cells

Overcoming the barriers of the P53 dysfunction to cure blood cancers

Exciting new immunosuppressive therapy treatment for aplastic anaemia

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

First targeted therapy for multiple myeloma effective against hard-to-treat disease

First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival

Exciting evidence for first all-oral treatment for relapsed and treatment-resistant multiple myeloma

Study finds new use for rituximab in acute lymphoblastic leukaemia

First targeted therapy for multiple myeloma effective against hard-to-treat disease

First targeted therapy for genetically defined subset with acute myeloid leukaemia significantly improves survival

Variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified

Immunotherapy makes patients’ tumours "melt away"

Quality assessment looking at rivaroxaban for cancer-related thrombosis

Guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients

Genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia

Tosedostat for elderly acute myeloid leukaemia

ASH 2015: Monoclonal antibodies for multiple myeloma

Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma

Daratumumab for multiple myeloma

Children most at risk of over-reporting adherence to at-home chemotherapy regimen

Cancer-associated thrombosis: Switching patients to warfarin after 6-month completion of anticoagulant treatment

Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis

Researchers identify children most at risk of over-reporting adherence to at-home chemotherapy regimen

Research provides guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients

Promising new strategy for treating children with acute lymphocytic leukaemia

Comment: Whole exome sequencing finds genes associated with autoimmune platelet disorder in children

Comment: Classification system based on cytogenetics and treatment response identifies leukaemia patients with high-risk clinical features

Comment: Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia

Comment: Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified

Engineered cells to target multiple myeloma

Whole exome sequencing finds genes associated with autoimmune platelet disorder in children

Classification system based on cytogenetics and treatment response identifies leukaemia patients with high risk clinical features with outstanding outcomes

Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia

Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified